Journal Scans
Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
Maintenance Rituximab Achieves Long-Term Remission in Follicular Lymphoma
G Martinelli, S-FH Schmitz, U Utiger, T Cerny, U Hess, S Bassi, E Okkinga, R Stupp, R Stahel, M Heizmann, D Vorobiof, A Lohri, P-Y Dietrich, E Zucca, M Ghielmini
20100709
2010 Aug 9
J Clin Oncol
Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
J Clin Oncol. 2010 Aug 9;[Epub Ahead of Print], G Martinelli, S-FH Schmitz, U Utiger, T Cerny, U Hess, S Bassi, E Okkinga, R Stupp, R Stahel, M Heizmann, D Vorobiof, A Lohri, P-Y Dietrich, E Zucca, M Ghielmini
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Because follicular lymphoma (FL) is largely considered incurable, treatment is aimed at symptom control. The standard of care for patients with FL is rituximab with chemotherapy. However, long-term rituximab monotherapy is considered a viable alternative that is associated with extended remissions and low toxicity. In this study, Martinelli et al report the long-term results of a prospective clinical trial evaluating the use of single-agent rituximab, including rituximab maintenance therapy. The...
